Table 2 TriAS independently segregates survival of AML patients even including other expression-based risk scores: multivariate Cox regression analysis for OS of AML patients from the TCGA training and the NTUH validation set 1 using cytogenetic risk, gender, age >65Â years, and TriAS as well as scores developed by Marcucci, Chuang, and Li
From: A three-gene expression-based risk score can refine the European LeukemiaNet AML classification
| Â | HR multivariate | p value multivariate |
|---|---|---|
TCGA training set (n = 161) | ||
 Cytogenetic risk group poor | 1.516 (0.887–2.594) | 0.1284 |
 Cytogenetic risk group favorable | 0.651 (0.329–1.290) | 0.2186 |
 Gender (female) | 1.343 (0.894–2.018) | 0.1557 |
 Age > 65 | 3.817 (2.429–5.999) | <0.0001 |
 Marcucci score | 1.090 (0.661–1.800) | 0.7349 |
 Chuang score | 0.993 (0.949–1.039) | 0.7603 |
 Li score | 1.432 (0.861–2.380) | 0.1661 |
 TriAS | 2.148 (1.659–2.782) | <0.0001 |
NTUH validation set (n = 221) | ||
 Cytogenetic risk group poor | 2.229 (1.424–3.489) | 0.0005 |
 Cytogenetic risk group favorable | 0.473 (0.256–0.873) | 0.0167 |
 Gender (female) | 0.856 (0.583–1.257) | 0.4283 |
 Age > 65 | 2.252 (1.378–3.680) | 0.0012 |
 Marcucci score | 0.952 (0.591–1.533) | 0.8402 |
 Chuang score | 1.081 (1.040–1.124) | <0.0001 |
 Li score | 1.126 (0.710–1.786) | 0.6133 |
 TriAS | 1.337 (1.031–1.733) | 0.0285 |